Published in Gastroenterology on May 01, 2004
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2011) 2.33
Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A (2004) 2.03
Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell (2008) 1.75
Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther (2011) 1.36
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
Wnt-β-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology (2011) 1.19
Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res (2009) 1.07
Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.01
S-adenosylmethionine regulates apurinic/apyrimidinic endonuclease 1 stability: implication in hepatocarcinogenesis. Gastroenterology (2008) 0.95
Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol (2011) 0.94
Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol (2005) 0.94
Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol (2005) 0.85
Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1. Can J Gastroenterol Hepatol (2015) 0.82
Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice. Liver Int (2011) 0.79
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One (2011) 0.79
Altered {beta}-catenin accumulation in hepatocellular carcinomas of diethylnitrosamine-exposed rhesus macaques. Toxicol Pathol (2008) 0.78
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun (2015) 0.78
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis. Am J Pathol (2011) 0.78
Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett (2015) 0.77
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer (2013) 0.77
Mouse models of liver cancer: Progress and recommendations. Oncotarget (2015) 0.77
Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World J Gastroenterol (2008) 0.77
Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions. Cancer Sci (2015) 0.77
Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease. Oncotarget (2016) 0.75
Decoding human liver cancer signatures. Gastrointest Cancer Res (2008) 0.75
Identification of structural DNA variations in human cell cultures after long-term passage. Cell Cycle (2015) 0.75
Neonatal tumours. Pediatr Surg Int (2013) 0.75
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett (2005) 1.45
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41
Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene (2005) 1.39
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology (2006) 1.34
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology (2009) 1.33
Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology (2012) 1.33
Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology (2004) 1.33
Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development (2009) 1.31
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology (2008) 1.29
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology (2006) 1.27
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (2010) 1.26
Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. J Hepatol (2005) 1.25
Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol (2005) 1.25
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med (2010) 1.23
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med (2012) 1.21
Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am J Pathol (2005) 1.18
Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One (2010) 1.17
2-acetylaminofluorene dose-dependent differentiation of rat oval cells into hepatocytes: confocal and electron microscopic studies. Hepatology (2004) 1.17